Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T19:58:44.894Z.
Calculation as of: 2026-10-06T19:58:44.894Z.
Quote observation: 2026-10-06T19:49:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 92121ceff5fa8810ba44f4cfbc32d43134c549094e5f0bfbc79a82dde622c70d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Revelation Biosciences, Inc.
Market Cap
$2.93M
EBITDA Yield
N/A
| NAME | MARKET CAP | EBITDA YIELD |
|---|---|---|
| Revelation Biosciences, Inc. (REVB) | $2.93M | N/A |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.07M | N/A |
| Universe Pharmaceuticals Inc. (UPC)vs › | $2.80M | N/A |
| IceCure Medical Ltd (ICCM)vs › | $2.93M | N/A |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.14M | N/A |
| iSpecimen Inc. (ISPC)vs › | $2.69M | N/A |
| MBody AI Ltd. (MBAI)vs › | $3.25M | N/A |
| Aethlon Medical, Inc. (AEMD)vs › | $3.21M | N/A |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.23M | N/A |
| Nuwellis, Inc. (NUWE)vs › | $2.56M | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
